Research findings last week included US vaccines maker Vaxcyte releasing highly impressive Phase III data for its VAX-31, for ...

A U.S. specialty biopharmaceutical company focused on dermatology, with operations centered on commercialization and late-stage development. The company is publicly listed on NYSE American under ...

A biotech company developing new targeted therapeutics for solid tumors. TwoStep launched in July 2024 following a successful $6.5 million seed round led by NFX, with participation from other ...

A clinical-stage biopharmaceutical company with operational hubs in the United States and China. The company maintains offices in New Jersey and in multiple China locations (including Shanghai and ...

A clinical-stage biopharmaceutical company leveraging proprietary peptide technology to develop therapeutics for inflammation, hematology, and metabolic diseases, with multiple late-stage programs ...

The rename to Nxera Pharma, effective June 2024, marked a deliberate break from a dual-identity that reflected the 2015 Heptares acquisition rather than a unified company vision. The new brand aligns ...

A US biotechnology company targeting severe autoimmune diseases, Priovant Therapeutics won FDA approval in August 2026 for Lisraya (brepocitinib), the first oral drug indicated for dermatomyositis in ...

US biopharma company Mineralys Therapeutics today announced the presentation of a new analysis from its pivotal Phase III ...

Given the impact of the illegal medicines trade on public health in Latin America, on confidence in the health system and on ...

US biotech Outlook Therapeutics, which is specializing in the development and commercialization of Lytenava (bevacizumab-vikg ...

Leading Swiss contract development and manufacturing organization (CDMO) Lonza and Onava, a US biotech building an AI-native ...

Israel-based Teva Pharmaceutical Industries US subsidiary today revealed that the US Food and Drug Administration (FDA) has ...